{"id":968,"date":"2022-08-24T08:08:04","date_gmt":"2022-08-24T08:08:04","guid":{"rendered":"http:\/\/clinicalbiochemistry.net\/?page_id=968"},"modified":"2022-08-24T08:08:06","modified_gmt":"2022-08-24T08:08:06","slug":"self-funded-phd-opportunity-cardiovascular-disease-in-esrd","status":"publish","type":"page","link":"http:\/\/clinicalbiochemistry.net\/?page_id=968","title":{"rendered":"Self-Funded PhD Opportunity: Cardiovascular Disease in ESRD"},"content":{"rendered":"\n

A Multi-Omics approach to understanding cardiovascular risk in patients with End-Stage Kidney Disease.<\/h2>\n\n\n\n
\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n<\/figure>\n\n\n\n

End-stage Kidney failure, also known as End-stage Kidney Disease (ESKD), is the final, irreversible stage of chronic kidney disease, where kidney function has worsened to the point that the kidneys can no longer function independently. Cardiovascular complications rather than impaired renal function are the leading cause of death in ESKD. This is due to CKD\/ESKD is a chronic systemic proinflammatory state contributing to vascular and myocardial remodelling, atherosclerosis, vascular calcification and senescence, cardiac fibrosis and valve calcification and complex dyslipidaemia. Also, in CKD, due to uraemia, there is disruption of the microbiome and gut barrier function that allows translocation of endotoxin and bacterial metabolites to the systemic circulation, contributing to inflammation and associated cardiovascular disease. In this respect, CKD mimics accelerated ageing of the cardiovascular system. In 2009, an estimated 7,000 extra strokes and 12,000 extra myocardial infarctions per year were due to CKD in the UK, costing the NHS over \u00a3170 million.<\/p>\n\n\n\n

Circulating blood cardiac biomarkers provide an insight into various aspects of cardiovascular structure and function, including myocyte injury, myocyte stress inflammation, and fibrosis. There are several promising new cardiovascular biomarkers (soluble suppression of tumorigenesis-2 (ST-2), galectin-3, and myosin chain), but their role in risk stratification in ESKD is unknown. In ESKD, lipoprotein particle size and composition is altered, with an upregulation of small, dense, low-density lipoprotein (LDL) particles that remain in the circulation for longer and have intrinsic properties capable of inducing endothelial inflammation. High-density lipoprotein (HDL) becomes dysfunctional, with impaired maturation, altered molecular composition, depressed anti-oxidant\/anti-inflammatory functions, and clearance of triglyceride-rich lipoproteins and their atherogenic remnants show altered molecular composition and elevated plasma levels in ESKD. As a result of microbiome dysregulation, there is elevated levels of endotoxin, Trimethylamine N-oxide (TMAO), Indoxyl sulfate (IS) and Cresyl sulfate (pCS), which are associated with cardiovascular disease in ESKD. <\/p>\n\n\n\n

The objectives<\/strong><\/p>\n\n\n\n

  1. To identify metabolomic and genomic patterns associated with cardiovascular disease in ESKD.<\/li>
  2. Assess the utility of putative metabolomic and genomic pattern in predicting deterioration in cardiac function and incidence major adverse cardiac events (MACE) in patients with ESKD.<\/li>
  3. Determine the utility of existing and new cardiac biomarkers in predicting deterioration in cardiac function and incident MACE in patients with ESKD. <\/li>
  4. To characterise the microbiome in patients with ESKD. <\/li><\/ol>\n\n\n\n

    Please follow the link for more details about how to apply: Link to Find a PhD<\/span><\/a> <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    A Multi-Omics approach to understanding cardiovascular risk in patients with End-Stage Kidney Disease. End-stage Kidney failure, also known as End-stage Kidney Disease (ESKD), is the final, irreversible stage of chronic kidney disease, where kidney function has worsened to the point<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"jetpack_post_was_ever_published":false,"_links_to":"","_links_to_target":""},"jetpack_shortlink":"https:\/\/wp.me\/P9tPlw-fC","jetpack-related-posts":[{"id":519,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=519","url_meta":{"origin":968,"position":0},"title":"PhD Projects","date":"August 23, 2022","format":false,"excerpt":"We have a range of self funded PhD projects. Please contact us using the details on the adverts below. A Multi-Omics approach to understanding cardiovascular risk in patients with End-Stage Kidney Disease. End-stage Kidney failure, also known as End-stage Kidney Disease (ESKD), is the final, irreversible stage of chronic kidney\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2019\/02\/iStock_567368_MEDIUM.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":49,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=49","url_meta":{"origin":968,"position":1},"title":"Research Expertise","date":"December 17, 2017","format":false,"excerpt":"\u00a0 Research Expertise Cardiology Cardiovascular Disease Acute Cardiology Acute Coronary Syndromes Diagnostics Heart Failure Diagnostics Heart Failure Physiology and Patho-physiology Angiogenesis Cardiac Biomarkers Diagnostic and Prognostic role of Cardiac Biomarkers Methodological Knowledge Immunoassay Point of Care Testing (Near Patient Testing) Cell Biology Clinical Trials Diagnostic Studies Cohort Studies Biomarker development\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":51,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=51","url_meta":{"origin":968,"position":2},"title":"Research","date":"December 17, 2017","format":false,"excerpt":"Dr McDowell's research interest is focused on the translational aspects of the\u00a0development and clinical validation of biomarkers for diagnostic and\/or prognostic testing in cardiology, heart failure and oncology,\u00a0supported by developing an understanding of the pathophysiology of disease. Research underpins specific clinical objectives: \u00a0 \u00a0 Generating and validating accurate and timely\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":203,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=203","url_meta":{"origin":968,"position":3},"title":"Book Chapter: Gastrointestinal Disorders and Malabsorption","date":"December 24, 2017","format":false,"excerpt":"McDowell, G & Brydon, G. (2016) \u2018Gastrointestinal Disorders and Malabsorption.\u2019 In: Admed, N. (ed) (2016) Fundamentals of Biomedical Science Clinical Biochemistry. 2nd Edition. Oxford University Press. pp 420-444. (25 pages) Learning objectives After studying this chapter you should be able to: Explain the different functions of acid in the stomach\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2017\/12\/Clinical-Biochemistry-Book-pages-1-227x300.png?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":629,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=629","url_meta":{"origin":968,"position":4},"title":"Risk Factors and AMI","date":"February 7, 2019","format":false,"excerpt":"Body, R.,\u00a0McDowell, G.,Carley, S. & Mackway-Jones, K. (2008) \u2018Do risk factors for chronic coronary heart disease help diagnose acute myocardial infarction in the emergency department.\u2019\u00a0Resuscitation79 pp. 41-45.\u00a0 Background:Hypertension, hyperlipidaemia, diabetes mellitus, tobacco smoking and a family history of premature coronary artery disease are known to be risk factors for the\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2019\/01\/Risk-factors-for-ED-diagnosis-e1549807935709.png?fit=400%2C313&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":193,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=193","url_meta":{"origin":968,"position":5},"title":"Book Chapter: Thyroid Function","date":"December 24, 2017","format":false,"excerpt":"McDowell, G. (2016) \u2018Thyroid Disease\u2019. In: Admed, N. (ed) (2016) Fundamentals of Biomedical Science Clinical Biochemistry. 2nd Edition. Oxford University Press. pp 284-299. (16 pages) \u00a0 Learning objectives After studying this chapter you should be able to: Describe the structure and function of the thyroid gland Explain the function of\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2017\/12\/Clinical-Biochemistry-Book-pages-1-227x300.png?resize=350%2C200","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/968"}],"collection":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=968"}],"version-history":[{"count":3,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/968\/revisions"}],"predecessor-version":[{"id":976,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/968\/revisions\/976"}],"wp:attachment":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}